1. The search for better treatment strategies for mansonellosis: an expert perspective.
- Author
-
Ferreira MU, Crainey JL, and Gobbi FG
- Subjects
- Adult, Animals, Humans, Mansonella, Ivermectin therapeutic use, Anti-Bacterial Agents therapeutic use, Arthralgia complications, Arthralgia drug therapy, Mansonelliasis complications, Mansonelliasis drug therapy, Anthelmintics therapeutic use
- Abstract
Introduction: Four species of the Mansonella genus infect millions of people across sub-Saharan Africa and Central and South America. Most infections are asymptomatic, but mansonellosis can be associated with nonspecific clinical manifestations such as fever, headache, arthralgia, and ocular lesions ( M. ozzardi ); pruritus, arthralgia, abdominal pain, angioedema, skin rash, and fatigue ( M. perstans and perhaps Mansonella sp. 'DEUX'); and pruritic dermatitis and chronic lymphadenitis ( M. perstans )., Areas Covered: We searched the PubMed and SciELO databases for publications on mansonelliasis in English, Spanish, Portuguese, or French that appeared until 1 May 2023. Literature data show that anthelmintics - single-dose ivermectin for M. ozzardi , repeated doses of mebendazole alone or in combination with diethylcarbamazine (DEC) for M. perstans , and DEC alone for M. streptocerca - are effective against microfilariae. Antibiotics that target Wolbachia endosymbionts, such as doxycycline, are likely to kill adult worms of most, if not all, Mansonella species, but the currently recommended 6-week regimen is relatively impractical. New anthelmintics and shorter antibiotic regimens (e.g. with rifampin) have shown promise in experimental filarial infections and may proceed to clinical trials., Expert Opinion: We recommend that human infections with Mansonella species be treated, regardless of any apparent clinical manifestations. We argue that mansonellosis, despite being widely considered a benign infection, may represent a direct or indirect cause of significant morbidity that remains poorly characterized at present.
- Published
- 2023
- Full Text
- View/download PDF